Korro Bio, Inc.

NASDAQ•KRRO

執行長: Mr. Nessan Bermingham Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

聯絡資訊

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

市值

$120.54M

本益比 (TTM)

-1.0

17.9

股息率

52周最高

$55.89

52周最低

$5.20

52周範圍

15%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基於 8 年期基本面

疲弱 • 2.2 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2018-2025

財務儀表板

Q4 2025 數據

營業收入

$1.29M+0.00%

近4季度走勢

每股收益

-$5.33+0.00%

近4季度走勢

自由現金流

-$17.79M+0.00%

近4季度走勢

2025 Q3 財報亮點

核心亮點

Collaboration Revenue Recognized Nine months collaboration revenue reached $5.1M, compared to zero recognized in the prior nine months period.

R&D Expenses Increased Research and development expenses rose $7.9M to $54.6M for nine months, funding pipeline advancement.

KRRO-121 Candidate Nominated Nominated KRRO-121 for UCD/HE treatment; planning first-in-human regulatory filing in second half 2026.

Cash Runway Extended Cash, cash equivalents, and marketable securities totaled $102.5M, funding operations into second half 2027.

關注風險

KRRO-110 Program Pivoting KRRO-110 failed to meet AATD protein goals; pivoting delivery method, which may cause development delays.

Increased Net Loss Nine months net loss widened to $67.2M from $62.4M; requires substantial future capital infusion.

Workforce Reductions Impact Implemented two workforce reductions (May and November 2025); future expansion efforts face integration challenges.

Novo Nordisk Collaboration Paused Novo Nordisk collaboration paused for 12 months starting November 2025, suspending expected revenue recognition.

未來展望

KRRO-121 Clinical Trial Filing Plan to submit regulatory filing for KRRO-121 first-in-human trial during the second half of 2026.

AATD Candidate Nomination Prioritizing GalNAc-conjugated AATD program; expect to nominate a development candidate during 2026.

Continued High R&D Spending Expect substantial increase in R&D expenses to advance pipeline through clinical development stages.

Pursuing Additional Financing Will pursue additional cash resources through public or private equity offerings, collaborations, or debt financings.

同行對比

營業收入 (TTM)

AMRN

$183.87M

-19.6%

ADCT

$81.36M

+14.9%

CLLS

$75.27M

+158.9%

毛利率 (最新季度)

AMRN

119.2%

+7.3pp

ALT

100.0%

-299200.0pp

CLLS

93.3%

+10.5pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$676.91M	-4.1	-92.3%	11.8%
RCKT	$513.53M	-2.4	-65.8%	7.5%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-20.3%

增長承壓

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年3月17日

每股收益:-$1.93

營業收入:$425.00K

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料